BrainsWay to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022
28 févr. 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Feb. 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces Publication of Results Demonstrating Efficacy of Deep TMS™ in Treating Anxiety Symptoms Comorbid to Depression
23 févr. 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
01 févr. 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Feb. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS™ for the Treatment of OCD
31 janv. 2022 07h30 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Jan. 31, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board
26 janv. 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Jan. 26, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of...
BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System
12 janv. 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Israel, Jan. 12, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive...
BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects
09 déc. 2021 07h30 HE
|
BrainsWay
Randomized, Placebo-Controlled, Double-Blind Pilot Study Evaluated Deep TMS Treatment in Reducing Alcohol Consumption and Craving for Adults with Alcohol Use Disorder Study Findings to be Featured...
BrainsWay to Present at the Sidoti December Micro-Cap Investor Conference
30 nov. 2021 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Nov. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights
17 nov. 2021 07h30 HE
|
BrainsWay
Revenue Growth of 34% Year-over-Year in Q3 2021 Received Regulatory Clearance for Deep TMS™ System for Treatment of Anxious Depression Conference Call to be held Today at 8:30 AM ET BURLINGTON,...
BrainsWay to Report Third Quarter 2021 Financial Results on November 17, 2021
03 nov. 2021 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...